Industry Connect with Takeda Pharmaceuticals and Shonan Health Innovation Park
Takeda Pharmaceuticals and Shonan Health Innovation Park have launched a joint grant call for specific areas of interest in an effort to accelerate and nurture innovative seeds/technologies in Australia and South Korea.
Successful applicants will receive approximately AUD 115,000 per year for 3 years, incubation and space at Shonan iPark and mentorship and coaching from research experts of Takeda.
The Research Incubation Program will focus on neurological and neuromuscular disorders:
Homeostatic therapeutic approach
Novel therapeutics against hereditary disorders
Groundbreaking therapeutic platform.
This call for proposals has now closed.
Areas of focus
Homeostatic Therapeutic Approach
– brain cleansing
– genome instability
– phase separation
– senolysis
Novel Therapeutics against Hereditary Disorders
Groundbreaking Therapeutic Platform
– biologics (antibody, protein)
– small molecule of DNA/RNA modifiers
– polypharmacology
– technopharmaceutical
Next steps
Join online information session on 23 June:
– QBI Level 7 Auditorium
– register to receive Zoom details
Download application form and discuss with UniQuest
Internal deadline: submit your application to takeda@uniquest.com.au by 22nd July for review and feedback
Deadline to Takeda: UniQuest will coordinate submissions to Takeda by 31st July.
Online information session details
Time
3:00 - 4:00pm (AEST time)
Date
Thursday, 23 June 2022
Venue
QBI Level 7 Auditorium
Queensland Brain Institute (#79) St Lucia Campus
VIA ZOOM
RSVP
To rsvp@uniquest.com.au for Zoom details or to register in-person attendance
For more information in your research area, contact:
Dr Craig Belcher
c.belcher@uniquest.com.au
Dr Tamsin Terry
t.terry@uniquest.com.au
Dr David Markwell
d.markwell@uniquest.com.au
Dr George Adamson
g.adamson@uniquest.com.au
Julian Vultaggio
j.vultaggio@uniquest.com.au
